The appointments mark an important milestone for Discovery Evolution as the company advances its proprietary computational platform designed to bridge digital molecular design with clinical translation. The company focuses on discovering biologics against previously inaccessible targets, combining advanced computational modeling with translational biotechnology expertise.
“Bringing together this caliber of scientific leadership is a major step forward for Discovery Evolution,” said Harold P. de Vladar, Founder and CEO of Discovery Evolution. “Each advisor brings deep expertise across biologics discovery, translational medicine, AI-enabled drug development, and biomedical innovation. Their guidance will be instrumental as we scale our platform and pursue transformative therapies for patients who need them most.”
Dr. Catherine Hutchings is a recognized leader in antibody drug discovery with with nearly three decades of experience across biotechnology and pharmaceutical research. She previously held leadership roles at Cambridge Antibody Technology (now part of MedImmune/AstraZeneca) and Heptares Therapeutics (now Nxera Pharma UK), where she contributed to pioneering work in GPCR antibody discovery. Her expertise spans biologics engineering, complex membrane protein targets, and platform development for next-generation therapeutics.
“Discovery Evolution is tackling one of the most exciting frontiers in biotechnology,” said Dr. Hutchings. “The company’s approach to combining computational discovery with biologics innovation has the potential to unlock targets that have historically remained inaccessible to conventional therapeutic approaches.”
Dr. Bryn Williams-Jones is an experienced drug discovery executive with extensive expertise in AI-driven pharmaceutical research, bioinformatics, and translational drug development. Over a career spanning more than 30 years, he has held leadership roles across biotech and pharmaceutical organizations, integrating machine learning and advanced data science into therapeutic discovery workflows.
“Digital approaches are fundamentally reshaping how we identify and develop therapeutics,” said Dr. Williams-Jones. “Discovery Evolution is building a platform that meaningfully connects computational intelligence with biological relevance, creating new opportunities to accelerate biologics discovery and improve drug development success.”
Professor Krista Rombouts is an internationally recognized scientist and Professor of Experimental Liver and Digestive Sciences at University College London (UCL). Her research has significantly advanced the understanding of fibrosis, tissue regeneration, tumour-stromal interactions, and liver disease biology.
She has authored numerous highly cited publications and is widely respected for her translational research contributions in regenerative medicine and complex disease mechanisms.
“Discovery Evolution represents an important new model for translational biotechnology,” said Professor Rombouts. “Its multidisciplinary approach has the potential to accelerate the development of novel biologics for diseases where therapeutic innovation is urgently needed.”
The establishment of this Scientific Advisory Board marks a pivotal step in Discovery Evolution's journey to redefine how novel biologics are discovered and developed.
About Discovery Evolution
Discovery Evolution is a Vienna-based deep-tech biotechnology company with a proprietary platform for the digital discovery of novel biologics against complex and historically difficult-to- drug targets. By integrating computational biology, AI-driven molecular modeling, and in silico directed evolution, the company accelerates the discovery and engineering of biologics to enable transformative therapeutics for diseases with significant unmet medical needs. Find out more about Discovery Evolution at www.discovery-evolution.com
Contact
office(at)discovery-evolution.com
Karl-Farkas-Gasse 18. 1030 Vienna, Austria
www.discovery-evolution.com